Stay updated on Cabozantinib for NSCLC Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for NSCLC Brain Metastases Clinical Trial page.

Latest updates to the Cabozantinib for NSCLC Brain Metastases Clinical Trial page
- ChecktodayChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 in the page footer, indicating a minor version update that does not alter trial content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedMinor formatting changes were made to the study's location section: the header changed from 'Pennsylvania Locations' to 'Locations' with a subheading 'Pennsylvania', and the page revision tag was updated; the 'HHS Vulnerability Disclosure' footer link was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing the previous Revision: v3.2.0.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoved the government funding and operating status notice from the page; core study details such as inclusion criteria, endpoints, and treatment information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedThe study status is updated to Terminated due to slow patient accrual. Results have been added with Results First Posted on 2020-09-16.SummaryDifference0.4%

- Check101 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference2%

Stay in the know with updates to Cabozantinib for NSCLC Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for NSCLC Brain Metastases Clinical Trial page.